Sung Hyuna, Cho Soo Yoon, Ma Seong Hyeok, You Jin Sun, Yoon Mi Young, Yoon Sang Sun
Department of Microbiology and Immunology Yonsei University College of Medicine Seoul Republic of Korea.
Institute for Immunology and Immunological Diseases Yonsei University College of Medicine Seoul Republic of Korea.
mLife. 2025 Jul 30;4(4):397-408. doi: 10.1002/mlf2.70027. eCollection 2025 Aug.
Inflammatory bowel disease (IBD) is a chronic condition characterized by intestinal inflammation and gut dysbiosis, with limited treatment options primarily focused on immune-modulating therapies. Among potential therapeutic agents, butyrate has emerged as a promising candidate due to its anti-inflammatory and gut-restorative properties. However, direct administration of butyrate poses significant challenges, including its rapid absorption, uneven distribution within the intestinal tract, and an unpleasant odor that reduces patient compliance. To address these issues, we evaluated the therapeutic potential of BM107, a strain selected for its superior butyrate-producing capabilities and established bacterial safety. BM107 efficiently hydrolyzed tributyrin (TB), a butyrate prodrug, producing substantial butyrate levels in TB-supplemented media. In a dextran sodium sulfate-induced colitis mouse model, co-administration of BM107 and the TB diet significantly improved inflammatory indices, such as reduced disease activity index scores, increased colon length, and restored body weight. Additionally, this combination treatment markedly improved gut microbiome composition, restoring microbial diversity and balance. Furthermore, butyrate levels in the cecum contents of the TB + BM107 group were restored to levels comparable to those in healthy controls, demonstrating the ability of this approach to promote gut homeostasis and intestinal recovery. These findings highlight the therapeutic potential of BM107 combined with a TB diet as a safe, effective, and innovative strategy for addressing gut dysbiosis and inflammation in IBD, paving the way for the development of microbiome-based bacterial therapeutics to improve patient outcomes.
炎症性肠病（IBD）是一种以肠道炎症和肠道微生物群失调为特征的慢性疾病，目前的治疗选择有限，主要集中在免疫调节疗法上。在潜在的治疗药物中，丁酸盐因其抗炎和恢复肠道功能的特性而成为一种有前景的候选药物。然而，直接施用丁酸盐存在重大挑战，包括其快速吸收、在肠道内分布不均以及难闻的气味，这会降低患者的依从性。为了解决这些问题，我们评估了BM107的治疗潜力，BM107是一种因其卓越的丁酸盐生产能力和已确定的细菌安全性而被挑选出的菌株。BM107能有效水解丁酸前体药物三丁酸甘油酯（TB），在补充了TB的培养基中产生大量丁酸盐。在葡聚糖硫酸钠诱导的结肠炎小鼠模型中，联合施用BM107和含TB的饮食显著改善了炎症指标，如降低疾病活动指数评分、增加结肠长度和恢复体重。此外，这种联合治疗显著改善了肠道微生物群组成，恢复了微生物多样性和平衡。此外，TB + BM107组盲肠内容物中的丁酸盐水平恢复到与健康对照组相当的水平，表明这种方法能够促进肠道稳态和肠道恢复。这些发现突出了BM107与含TB的饮食联合使用作为一种安全、有效且创新的策略来解决IBD中的肠道微生物群失调和炎症的治疗潜力，为开发基于微生物群的细菌疗法以改善患者预后铺平了道路。
